Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

172.97
-1.3700-0.79%
Post-market: 172.970.00000.00%16:50 EDT
Volume:887.28K
Turnover:154.38M
Market Cap:9.06B
PE:-45.90
High:177.91
Open:174.00
Low:172.48
Close:174.34
52wk High:260.19
52wk Low:117.30
Shares:52.38M
Float Shares:43.83M
Volume Ratio:0.90
T/O Rate:2.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:108.76
PE(LYR):-46.98

Loading ...

Axsome Therapeutics Schedules Third-Quarter 2026 Financial Results Release and Conference Call

Reuters
·
Yesterday

Movement Alert|Axsome Therapeutics Falls 5.46% in Regular Trading, Deutsche Bank Lowers Price Target Amid Profit-Taking Pressure

Market Focus
·
Sep 30

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), ClearPoint Neuro (CLPT) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 29

Deutsche Bank Lowers Price Target on Axsome Therapeutics to $267 From $280, Keeps Buy Rating

MT Newswires Live
·
Sep 29

Axsome Therapeutics, Inc. : Deutsche Bank Cuts Target Price to $267 from $280

THOMSON REUTERS
·
Sep 29

Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says

MT Newswires Live
·
Sep 26

Axsome Therapeutics is Maintained at Buy by Truist Securities

Dow Jones
·
Sep 23

Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating

MT Newswires Live
·
Sep 23

Axsome Therapeutics, Inc. : Truist Securities Assumes Coverage with Buy Rating; Target Price $285 vs $200

THOMSON REUTERS
·
Sep 23

H.C. Wainwright Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 22

Axsome Presents Alzheimer’s Agitation Caregiver Survey Results at Psych Congress 2026

Reuters
·
Sep 21

Axsome Therapeutics Price Target Maintained with a $258.00/Share by Piper Sandler

Dow Jones
·
Sep 19

Axsome's Auvelity Launch Shows Early Strength in Alzheimer's Agitation, RBC Says

MT Newswires Live
·
Sep 18

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BioMarin Pharmaceutical (BMRN) and Axsome Therapeutics (AXSM)

TIPRANKS
·
Sep 18

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

GlobeNewswire
·
Sep 17

Movement Alert|Axsome Therapeutics Rises 6.24% in Regular Trading, Auvelity Prescription Growth Fuels Market Confidence

Market Focus
·
Sep 12

Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN)

TIPRANKS
·
Sep 10

Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million

Reuters
·
Sep 04

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Axsome Therapeutics' Auvelity Could Drive Revenue Beats After Launch in Alzheimer's Agitation, RBC Says

MT Newswires Live
·
Sep 01